Literature DB >> 24990308

The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: implications of continuous dopaminergic stimulation at night to treat the symptoms.

Fabrizio Stocchi1, Paola Stirpe.   

Abstract

Sleep problems are an under-emphasized cause of disability in Parkinson's disease (PD). Difficult sleep maintenance (light and fragmented sleep) and difficulties in initiating sleep are often the earliest and the most frequent symptoms observed in PD patients. In fluctuating patients, nocturnal akinesia, dystonia, painful cramps, and parasomnias may aggravate nocturnal problems. Treatment of sleep problems can be complex and challenging for the physicians. Dopaminergic treatment may improve some of the nocturnal symptoms in PD. In this paper, the effect of drugs and technique that ensure a more continuous delivery of dopaminergic drugs on sleep problems in PD is reviewed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24990308     DOI: 10.1007/s00702-014-1259-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  3 in total

1.  A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion.

Authors:  Maurizio Zibetti; Alberto Romagnolo; Aristide Merola; Lorenzo Priano; Elisa Montanaro; Serena Angrisano; Antonella Tribolo; Alessandro Cicolin; Leonardo Lopiano
Journal:  J Neurol       Date:  2017-04-19       Impact factor: 4.849

2.  Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.

Authors:  Rajesh Pahwa; Jason Aldred; Niodita Gupta; Emi Terasawa; Viviana Garcia-Horton; David R Steffen; Prasanna L Kandukuri; Vivek S Chaudhari; Yash J Jalundhwala; Yanjun Bao; Pavnit Kukreja; Stuart H Isaacson
Journal:  Neurol Ther       Date:  2022-02-22

3.  Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.

Authors:  Wei Xiang; Ya Qing Sun; Hui Chin Teoh
Journal:  Drug Des Devel Ther       Date:  2018-07-04       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.